OLEMA PHARMACEUTICALS INC (OLMA) — insider trading
Health Care · NASDAQ
OLEMA PHARMACEUTICALS INC (OLMA) has 16 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 16 (latest 2026-09-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | O'Byrne Jason | Officer (CHIEF FINANCIAL OFFICER) | Grant / award / vesting (derivative) | 650,000 | — | $0 | Form 4 |
| 2026-07-24 | Harmon Cyrus | Director | Open-market sale | 12,500 | $11.71 | $146.4K | Form 4 |
| 2026-07-23 | Harmon Cyrus | Director | Open-market sale | 12,500 | $11.58 | $144.7K | Form 4 |
| 2026-06-18 | Graham G. Walmsley | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | RAPPAPORT ANDREW | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | Raman Prakash | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | Horning Sandra | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | Larson Yi | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | CLARK IAN T | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | Hrustanovic Gorjan | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | Garland J. Scott | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | BUTITTA CYNTHIA M | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | Harmon Cyrus | Director | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-06-18 | BVF PARTNERS L P/IL; BIOTECHNOLOGY VALUE FUND L P; BVF I GP LLC; BIOTECHNOLOGY VALUE FUND II LP; BVF II GP LLC; Biotechnology Value Trading Fund OS LP; BVF Partners OS Ltd.; BVF GP HOLDINGS LLC; BVF INC/IL; LAMPERT MARK N | Director, Other | Grant / award / vesting (derivative) | 29,500 | — | $0 | Form 4 |
| 2026-04-28 | Raman Prakash | Director | Grant / award / vesting (derivative) | 24,150 | — | $0 | Form 4 |
| 2026-04-28 | Raman Prakash | Director | Grant / award / vesting (derivative) | 2,911 | — | $0 | Form 4 |
Ask the chat about OLMA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: OLEMA PHARMACEUTICALS INC (OLMA).
Last updated 2026-09-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.